Who has been buying Oncolys BioPharma Inc. stock?

8 distinct investors have filed 17 disclosed large-shareholding filings in Oncolys BioPharma Inc. (4588), most recently on 2026-02-05. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Oncolys BioPharma Inc. have?

Oncolys BioPharma Inc. has 17 buy-side and 31 sell-side disclosures on record, covering ¥21.0B ($135.6M) in total reported value, spanning 2021-03-22 to 2026-02-05.

Where does StockDrifts get Oncolys BioPharma Inc. insider data?

From EDINET large-shareholding (5%+) reports — the official filing system run by the Financial Services Agency (Japan). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from EDINET.

Do insider buys in Japanese stocks predict returns?

Not uniformly. StockDrifts scored 101,000+ Japanese large-shareholding filings on fixed 12-month forward returns and found the predictive power concentrated in specific filer types and filing patterns rather than spread evenly across all disclosures.

Oncolys BioPharma Inc. 4588

Company

オンコリスバイオファーマ株式会社Oncolys BioPharma Inc.

Investors

Buys

Total Value

¥21.0B ($135.6M)

Avg Return

+304.42%

Last Filing

2026-02-05

Oncolys BioPharma Inc. (4588) has 17 disclosed large-shareholding filings and 31 disclosed disposals on record, filed by 8 distinct investors. Together those filings cover ¥21.0B ($135.6M) in reported transaction value. The earliest filing StockDrifts holds for Oncolys BioPharma Inc. is dated 2021-03-22; the most recent is 2026-02-05. All of it is parsed from EDINET large-shareholding (5%+) reports, the official disclosure system operated by the Financial Services Agency (Japan). Across these filings the average return since disclosure is +304.42%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent filings

Date	Type	Source	Insider	Purpose	Shares	Price at filing	Return	Value
2026-05-20	SELL	Market Buy	五味大輔 Gomi Daisuke	passive	1.1M	¥2,041	-20.9%	¥676M ($4.4M)
2026-02-05	SELL	unknown	モルガン・スタンレーＭＵＦＧ証券株式会社 Morgan Stanley MUFG Securities Co., Ltd.	other	811.4K	¥1,778	-64.8%	¥1.5B ($9.4M)
2026-01-21	SELL	unknown	モルガン・スタンレー・アンド・カンパニー・エルエルシー Morgan Stanley & Co. LLC	other	593.2K	¥1,907	-53.6%	¥1.7B ($11.2M)
2026-01-21	BUY	unknown	モルガン・スタンレー・アンド・カンパニー・インターナショナル・ピーエルシー Morgan Stanley & Co. International plc	other	307.6K	¥1,907	+53.6%	¥901M ($5.8M)
2026-01-21	SELL	unknown	モルガン・スタンレーMUFG証券株式会社	other	726.5K	¥1,907	-53.6%	¥2.1B ($13.7M)
2026-01-16	BUY	Market Buy	五味大輔 Gomi Daisuke	passive	1.5M	¥1,943	+50.8%	¥2.9B ($18.5M)
2026-01-08	BUY	unknown	モルガン・スタンレー・アンド・カンパニー・エルエルシー Morgan Stanley & Co. LLC	other	750.1K	¥1,595	+83.7%	¥2.2B ($14.2M)
2026-01-08	BUY	unknown	モルガン・スタンレー・アンド・カンパニー・インターナショナル・ピーエルシー Morgan Stanley & Co. International plc	other	137.0K	¥1,595	+83.7%	¥401M ($2.6M)
2026-01-08	BUY	unknown	モルガン・スタンレーMUFG証券株式会社	other	808.3K	¥1,595	+83.7%	¥2.4B ($15.3M)
2025-11-21	SELL	unknown	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	1.2M	¥986	-197.2%	¥1.1B ($7.4M)
2025-10-27	SELL	unknown	株式会社三井住友銀行 Sumitomo Mitsui Banking Corporation	other	0	¥720	-306.9%	¥139M ($895K)
2025-10-27	SELL	unknown	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	2.6M	¥720	-306.9%	¥76M ($489K)
2025-10-17	BUY	unknown	株式会社三井住友銀行 Sumitomo Mitsui Banking Corporation	other	193.5K	¥700	+318.6%	¥135M ($874K)
2025-10-17	SELL	unknown	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	2.7M	¥700	-318.6%	¥244M ($1.6M)
2025-10-14	SELL	unknown	株式会社三井住友銀行 Sumitomo Mitsui Banking Corporation	other	67	¥783	-274.2%	¥38M ($246K)
2025-10-14	SELL	unknown	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	3.1M	¥783	-274.2%	¥185M ($1.2M)
2025-10-06	BUY	unknown	株式会社三井住友銀行 Sumitomo Mitsui Banking Corporation	other	48.1K	¥676	+333.4%	¥33M ($210K)
2025-10-06	SELL	unknown	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	3.4M	¥676	-333.4%	¥184M ($1.2M)
2025-08-22	SELL	unknown	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	3.7M	¥712	-311.5%	¥180M ($1.2M)
2025-08-20	SELL	unknown	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	4.0M	¥732	-300.3%	¥174M ($1.1M)
2025-08-12	BUY	unknown	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	4.3M	¥628	+366.6%	¥2.7B ($17.5M)
2024-10-23	BUY	Market Buy	エボリューション・キャピタル・マネジメント・エルエルシー Evolution Capital Management LLC	passive	0	¥650	+350.8%	-
2024-10-23	SELL	Market Buy	エボファンド Evo Fund	activist	1.1M	¥650	-350.8%	¥159M ($1.0M)
2024-10-22	BUY	Market Buy	エボリューション・キャピタル・マネジメント・エルエルシー Evolution Capital Management LLC	passive	0	¥617	+374.9%	-
2024-10-22	SELL	Market Buy	エボファンド Evo Fund	activist	1.4M	¥617	-374.9%	¥255M ($1.6M)
2024-10-21	BUY	Market Buy	エボリューション・キャピタル・マネジメント・エルエルシー Evolution Capital Management LLC	passive	0	¥621	+371.8%	-
2024-10-21	SELL	Market Buy	エボファンド Evo Fund	activist	1.8M	¥621	-371.8%	¥193M ($1.2M)
2024-10-18	SELL	Market Buy	エボファンド Evo Fund	activist	2.1M	¥620	-372.6%	¥340M ($2.2M)
2024-10-18	BUY	Market Buy	エボリューション・キャピタル・マネジメント・エルエルシー Evolution Capital Management LLC	passive	0	¥620	+372.6%	-
2024-09-20	BUY	private	エボリューション・キャピタル・マネジメント・エルエルシー Evolution Capital Management LLC	passive	0	¥582	+403.4%	-
2024-09-20	SELL	private	エボファンド Evo Fund	activist	2.7M	¥582	-403.4%	¥2M ($12K)
2024-08-21	BUY	private	エボリューション・キャピタル・マネジメント・エルエルシー Evolution Capital Management LLC	passive	0	¥621	+371.8%	-
2024-08-21	SELL	private	エボファンド Evo Fund	activist	3.1M	¥621	-371.8%	¥2M ($10K)
2024-08-14	BUY	private	エボリューション・キャピタル・マネジメント・エルエルシー Evolution Capital Management LLC	passive	0	¥620	+372.6%	-
2024-08-14	SELL	private	エボファンド Evo Fund	activist	3.3M	¥620	-372.6%	¥3M ($17K)
2024-08-01	BUY	private	エボリューション・キャピタル・マネジメント・エルエルシー Evolution Capital Management LLC	passive	0	¥559	+424.1%	-
2024-08-01	SELL	private	エボファンド Evo Fund	activist	3.8M	¥559	-424.1%	¥3M ($18K)
2024-07-08	BUY	private	エボリューション・キャピタル・マネジメント・エルエルシー Evolution Capital Management LLC	passive	0	¥569	+414.9%	-
2024-07-08	BUY	private	エボファンド Evo Fund	activist	4.4M	¥569	+414.9%	¥2.5B ($16.2M)
2024-02-22	SELL	subscription	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	914.0K	¥528	-454.9%	¥125M ($806K)
2024-01-11	SELL	subscription	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	1.1M	¥575	-409.6%	¥167M ($1.1M)
2023-12-22	SELL	subscription	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	1.5M	¥511	-473.4%	¥124M ($799K)
2023-11-22	SELL	subscription	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	1.7M	¥604	-385.1%	¥131M ($843K)
2023-11-08	SELL	subscription	株式会社三井住友銀行 Sumitomo Mitsui Banking Corporation	other	0	¥562	-421.4%	¥81M ($521K)
2023-11-08	BUY	subscription	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	1.9M	¥562	+421.4%	¥971M ($6.3M)
2023-10-31	SELL	subscription	株式会社三井住友銀行 Sumitomo Mitsui Banking Corporation	other	143.2K	¥541	-441.6%	¥12M ($76K)
2023-10-31	BUY	subscription	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	2.0M	¥541	+441.6%	¥968M ($6.2M)
2023-10-23	BUY	subscription	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	2.2M	¥542	+440.6%	¥1.0B ($6.7M)
2023-10-23	BUY	subscription	株式会社三井住友銀行 Sumitomo Mitsui Banking Corporation	other	162.5K	¥542	+440.6%	¥88M ($568K)
2023-10-13	SELL	subscription	SMBC日興証券株式会社 SMBC Nikko Securities Inc.	other	2.7M	¥618	-374.1%	¥96M ($617K)

Showing the 50 most recent of 60 filings.

Frequently asked questions

Who has been buying Oncolys BioPharma Inc. stock?: 8 distinct investors have filed 17 disclosed large-shareholding filings in Oncolys BioPharma Inc. (4588), most recently on 2026-02-05. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Oncolys BioPharma Inc. have?: Oncolys BioPharma Inc. has 17 buy-side and 31 sell-side disclosures on record, covering ¥21.0B ($135.6M) in total reported value, spanning 2021-03-22 to 2026-02-05.
Where does StockDrifts get Oncolys BioPharma Inc. insider data?: From EDINET large-shareholding (5%+) reports — the official filing system run by the Financial Services Agency (Japan). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from EDINET.
Do insider buys in Japanese stocks predict returns?: Not uniformly. StockDrifts scored 101,000+ Japanese large-shareholding filings on fixed 12-month forward returns and found the predictive power concentrated in specific filer types and filing patterns rather than spread evenly across all disclosures.

Source filings

Every trade listed above is disclosed in EDINET large-shareholding (5%+) reports, filed with the Financial Services Agency (Japan). View the original EDINET filings for Oncolys BioPharma Inc.. For how StockDrifts scores these disclosures, see the Japan insider signal tier research, or browse every Japanese stock we track.